Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Multiple Myeloma 85Recurrence 10Lymphoma 8Leukemia, Myeloid, Acute 6Immunoglobulin Light-chain Amyloidosis 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, Mantle-Cell 5Waldenstrom Macroglobulinemia 4Neoplasms, Plasma Cell 3Hematologic Neoplasms 3Plasmacytoma 2Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Leukemia, Plasma Cell 2Leukemia, Biphenotypic, Acute 2Carcinoma, Renal Cell 2Breast Neoplasms 2Amyloidosis 2Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Sarcoma, Kaposi 1Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Proteostasis Deficiencies 1Plasmablastic Lymphoma 1POEMS Syndrome 1Neurofibrosarcoma 1

Interventions

Cytarabine 82Etoposide 32Daunorubicin 31Idarubicin 26Filgrastim 26Mitoxantrone 22Busulfan 18Peripheral Blood Stem Cell Transplantation 17fludarabine phosphate 14Gemtuzumab 14Cyclophosphamide 14tipifarnib 11Clofarabine 10Azacitidine 10Radiotherapy 9Methotrexate 9Gene Expression Profiling 9sargramostim 8Flow Cytometry 8Granulocyte Colony-Stimulating Factor 7Decitabine 7Cyclosporine 7alvocidib 6Topotecan 6Tacrolimus 6Bortezomib 6Antilymphocyte Serum 6valspodar 5aldesleukin 5Vorinostat 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Acute × ixazomib × Clear all
NCT02030405 2019-04-05

Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Stanford University

Phase 2 Terminated
4 enrolled 10 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡